5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | BUY | BUY | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 11.79▼ | 11.79▼ | 11.75▼ | 11.44▲ | 12.45▼ |
MA10 | 11.79▼ | 11.74▼ | 11.64▲ | 11.44▲ | 14.98▼ |
MA20 | 11.79▼ | 11.61▲ | 11.60▲ | 12.24▼ | 16.25▼ |
MA50 | 11.77▼ | 11.50▲ | 11.38▲ | 15.29▼ | 19.33▼ |
MA100 | 11.65▲ | 11.37▲ | 11.45▲ | 16.43▼ | 17.60▼ |
MA200 | 11.58▲ | 11.49▲ | 13.79▼ | 19.83▼ | 44.60▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.006▼ | 0.015▲ | 0.027▲ | 0.169▲ | -0.608▼ |
RSI | 41.621▼ | 58.245▲ | 58.959▲ | 36.438▼ | 32.557▼ |
STOCH | 63.617 | 84.578▲ | 89.466▲ | 42.686 | 10.623▼ |
WILL %R | -86.364▼ | -27.632 | -14.000▲ | -43.046 | -90.611▼ |
CCI | -194.822▼ | 52.479 | 90.135 | 98.585 | -129.313▼ |
Wednesday, August 13, 2025 09:08 AM
NovoCure Limited (NASDAQ:NVCR) is one of the best medical device stocks to buy according to analysts. Leerink Partners analyst Jonathan Chang reiterated a Buy rating on NovoCure Limited (NASDAQ:NVCR) ...
|
Friday, August 08, 2025 11:43 AM
NVR (NVR) has been authorized by the board to repurchase up to $750M of its outstanding common stock, it said on Friday.
|
Tuesday, July 29, 2025 09:48 PM
Novocure's Tumor Treating Fields tech offers promise in oncology. NVCR trades at a compelling valuation after the recent stock price decline. See more here.
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
15/08/25 | 11.64 | 11.86 | 11.46 | 11.73 | 1,340,347 |
14/08/25 | 11.39 | 11.63 | 11.08 | 11.59 | 1,406,246 |
13/08/25 | 11.49 | 11.99 | 11.385 | 11.62 | 2,564,155 |
12/08/25 | 10.97 | 11.35 | 10.90 | 11.34 | 1,370,109 |
11/08/25 | 11.07 | 11.32 | 10.87 | 10.90 | 1,390,705 |
08/08/25 | 11.60 | 11.685 | 11.11 | 11.13 | 1,374,687 |
07/08/25 | 11.46 | 11.52 | 11.125 | 11.51 | 1,538,498 |
06/08/25 | 11.34 | 11.48 | 11.22 | 11.39 | 1,446,355 |
05/08/25 | 11.62 | 11.94 | 11.30 | 11.43 | 4,270,652 |
04/08/25 | 11.45 | 11.77 | 11.13 | 11.76 | 2,013,121 |
|
|
||||
|
|
||||
|
|